Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3

Archives of Gynecology and Obstetrics

Volumn 288, Issue 1, 2013, Pages 173-182

  Ma, Yaxi ^a   Weimer, Jörg ^b   Fredrik, Regina ^b   Adam Klages, Sabine ^b   Sebens, Susanne ^c   Caliebe, Amke ^d   Hilpert, Felix ^b   Eckmann Scholz, Christel ^b   Arnold, Norbert ^b   Schem, Christian ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b House 24 ^*  (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Apoptosis; Aurora kinase inhibitor; Epithelial ovarian cancer; Platinum; Polyploidy; SKOV3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; CARBOPLATIN; CASPASE 3; CASPASE 4; CASPASE 5; CASPASE 6; CASPASE 7; CISPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; OVARY CARCINOMA; PLOIDY; POLYPLOIDY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE B; CARBOPLATIN; CARCINOMA; CASPASE 3; CASPASE 7; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; ORGANOPHOSPHATES; OVARIAN NEOPLASMS; POLYPLOIDY; QUINAZOLINES;

EID: 84879419224     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2719-x     Document Type: Article

References (32)

1. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res Off J Am Assoc Cancer Res 14(6):1639-1648 (Pubitemid 351471713)
2. Tang C-JC, Lin C-Y, Tang TK (2006) Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 290(2):398-410 (Pubitemid 43163501)
3. Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH, Yuan CC (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455(5):431-440. doi: 10.1007/s00428-009- 0838-3
4. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A (2009) Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 89(12):1364-1373
5. Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, Danenberg K, Lenz HJ (2011) Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J 11(2):93-99
6. Esposito F, Libertini S, Franco R, Abagnale A, Marra L, Portella G, Chieffi P (2009) Aurora B expression in post-puberal testicular germ cell tumours. J Cell Physiol 221(2):435-439
7. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52(1):63-71. doi: 10.1016/j.jhep.2009.10.013
8. Kwon YJ, Lee SJ, Koh JS, Kim SH, Kim YJ, Park JH (2009) Expression patterns of aurora kinase B, heat shock protein 47, and periostin in esophageal squamous cell carcinoma. Oncol Res 18(4):141-151
9. Shen YC, Hu FC, Jeng YM, Chang YT, Lin ZZ, Chang MC, Hsu C, Cheng AL (2009) Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res 18(2):417-423. doi: 10.1158/1055-9965.EPI-08-0691
10. Tanaka S, Arii S (2010) Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma. J Hepato-Biliary-Pancreatic Sci 17(4):413-419. doi: 10.1007/s00534-009-0238-8
11. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res Off J Am Assoc Cancer Res 13(12):3682-3688. doi: 10.1158/1078-0432.CCR-06-2979 (Pubitemid 46955132)
12. Kaestner P, Stolz A, Bastians H (2009) Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 8(7):2046-2056. doi: 10.1158/1535-7163.MCT-09- 0323
13. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS (2006) Validating Aurora B as an anti-cancer drug target. J Cell Sci 119(Pt 17):3664-3675. doi: 10.1242/jcs.03145 (Pubitemid 44501870)
14. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X (2005) Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 579(16):3385-3391. doi: 10.1016/j.febslet.2005.04.080 (Pubitemid 40800286)
15. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH (2010) Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol cancer 9:42. doi: 10.1186/1476-4598-9-42
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA: Cancer J Clin 59(4):225-249. doi: 10.3322/caac.20006
17. Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(Suppl 5):20-28
18. Markman M (2008) Pharmaceutical management of ovarian cancer: current status. Drugs 68(6):771-789 (Pubitemid 351550530)
19. Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 65(4):707-717. doi: 10.1007/s00280-009-1076-8
20. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK (2008) Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res Off J Am Assoc Cancer Res 14(17):5437-5446. doi: 10.1158/1078-0432.CCR-07-4922
21. Fogh J (1975) Human tumor cells in vitro. Plenum Press, New York
22. The R Project for Statistical Computing. http://www.r-project.org/
23. Nair JS, de Stanchina E, Schwartz GK (2009) The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res Off J Am Assoc Cancer Res 15(6):2022-2030. doi: 10.1158/1078-0432.CCR-08-1826
24. Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS (2008) Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 6:79. doi: 10.1186/1479-5876-6- 79
25. Li J, Anderson MG, Tucker LA, Shen Y, Glaser KB, Shah OJ (2009) Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ 16(3):498-511. doi: 10.1038/cdd.2008.174
26. Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC cancer 6:201. doi: 10.1186/1471-2407-6-201 (Pubitemid 44314367)
27. Marumoto T, Zhang D, Saya H (2005) Aurora-A - a guardian of poles. Nat Rev Cancer 5(1):42-50. doi: 10.1038/nrc1526 (Pubitemid 40052324)
28. Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, Guma S, Phan L, Chou PC, Su CH, Zhang F, Chen JS, Yang TY, Yeung SC, Lee MH (2012) Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci USA 109(24):E1513-E1522. doi: 10.1073/pnas.1110287109
29. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52(15):4196-4199
30. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585-598 (Pubitemid 37159255)
31. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 279(19):19643-19648. doi: 10.1074/jbc.M311780200 (Pubitemid 38623401)
32. Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH (2011) Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22(2):431-437. doi: 10.1093/annonc/mdq344